netFormulary
 Report : Medicines with links to NICE 22/09/2017 18:07:13

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Restricted Use NICE TA 373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Restricted Use NICE TA 280: Rheumatoid Arthritis - Abatacept
Abatacept 10.01.03 Restricted Use NICE TA 195: after failure of a TNF
Adalimumab 10.01.03 Restricted Use NICE TA 373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 01.05 Restricted Use NICE TA 329: Adalimumab for moderately to severely active ulcerative colitis
Adalimumab 01.05 Restricted Use NICE TA 187: Crohns disease- Infliximab and Adalimumab
Adalimumab 13.05.03 Restricted Use NICE TA 146: Psoriasis - Adalimumab
Adalimumab 13.05.03 Restricted Use NICE TA 392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Aflibercept 11.08.02 Restricted Use NICE TA 294: Aflibercept in ARMD
Aflibercept 11.08.02 Restricted Use NICE TA 346: Aflibercept in DMO
Aflibercept 11.08.02 Restricted Use NICE TA 305: Aflibercept in macular oedema secondary to central RVO
Aflibercept 11.08.02 Restricted Use NICE TA 409: Aflibercept in Branch RVO
Alemtuzumab 08.02.04 Restricted Use NICE TA 312: Alemtuzumab for Multiple Sclerosis
Alirocumab 02.12 Restricted Use NICE TA 393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Restricted Use NICE TA 177: Alitretinoin for severe chronic hand eczema
Alteplase 02.10.02 Restricted Use NICE TA 264: Alteplase
Apixaban 02.08.02 Restricted Use NICE TA 341: Apixaban for DVT / PE
Apremilast 13.05.02 Restricted Use NICE TA 419: Apremilast for treating moderate to severe plaque psoriasis (Replaced NICE TA368 Nov 2016
Apremilast 10.01.03 Restricted Use NICE TA 433: Apremilast for treating active psoriatic arthritis
Aripiprazole Oral 04.02 Restricted Use NICE TA 292: Aripiprazole in Bipolar Disorder (adolescents)
Ataluren 10.02 Restricted Use NICE HST 3: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Basiliximab 08.02.02 Restricted Use NICE TA 85: Immunosuppressive therapy for renal transplantation in adults
Basiliximab 08.02.02 Restricted Use NICE TA 99: Immunosuppressive therapy for renal transplantation in children and adolescents
Boceprevir 05.03.03 Restricted Use NICE TA 253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
Canagliflozin 06.01.02.03 Restricted Use NICE TA 315: Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin 06.01.02.03 Restricted Use NICE TA 390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Capsacin cream 10.03.02 Restricted Use NICE CG 173: Neuropathic pain in adults
Capsacin cream 10.03.02 Restricted Use NICE CG 177: Osteoarthritis care and management
Certolizumab pegol 10.01.03 Restricted Use NICE TA 415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab pegol 10.01.03 Restricted Use NICE TA 383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab pegol 10.01.03 Restricted Use NICE TA 445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab pegol 10.01.03 Restricted Use NICE TA 375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (Replaced TA186 Jan 2016)
Ciclosporin ophthalmic emulsion 11.08.01 Restricted Use NICE TA 369: Ciclosporin for treating dry eye disease that has not improved...
Cinacalcet 09.05.01.02 Restricted Use NICE TA 117: Cinacalcet
Colesevelam 20 Restricted Use NICE Evidence Summary
Colistimethate sodium 05.01 Restricted Use NICE TA 276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Dabigatran etexilate 02.08.02 Restricted Use NICE TA 327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Daclatasvir 05.03.03 Restricted Use NICE TA 364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Restricted Use NICE TA 441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA 288: Dapaglifozin
Dapagliflozin 06.01.02.03 Formulary NICE TA 390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Darbepoetin Alfa 09.01.03 Restricted Use NICE NG 8: Anaemia management in people with chronic kidney disease
Dasabuvir 05.03.03 Restricted Use NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Degarelix 08.03.04.02 Restricted Use NICE TA 404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Restricted Use NICE TA 204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab 06.06.02 Restricted Use NICE TA 265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Dexamethasone Intravitreal Implant 11.04.01 Restricted Use NICE TA 229: Dexamethasone intravitreal implant for macular oedema secondary to retinal vein occlusion
Dexamethasone Intravitreal Implant 11.04.01 Restricted Use NICE TA 349: Dexamethasone intravitreal implant for diabetic macular oedema
Dimethyl Fumarate 08.02.04 Restricted Use NICE TA 320: Dimethyl fumarate for Multiple Sclerosis
Dulaglutide weekly 06.01.02.03 Restricted Use NICE NG 28: Type 2 diabetes in adults: management
Edoxaban 02.08.02 Restricted Use NICE TA 354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 02.08.02 Formulary NICE TA 355: Edoxaban in AF
Elbasvir and grazoprevir 05.03.03 Restricted Use NICE TA 413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Restricted Use NICE TA 293: Eltrombopag
Empagliflozin 06.01.02.03 Formulary NICE TA 336: Empagliflozin
Entecavir 05.03.03 Restricted Use NICE TA 153: Entecavir for the treatment of chronic hepatitis B
Epoetin alfa 09.01.03 Restricted Use NICE NG 8: Anaemia management in people with chronic kidney disease
Epoetin beta 09.01.03 Restricted Use NICE NG 8: Anaemia management in people with chronic kidney disease
Etanercept 10.01.03 Restricted Use NICE TA 373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 13.05.03 Restricted Use NICE TA 103: Psoriasis- etanercept
Evolocumab 02.12 Restricted Use NICE TA 394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide weekly 06.01.02.03 Restricted Use NICE NG 28: Type 2 diabetes in adults: management
Febuxostat 10.01.04 Restricted Use NICE TA 164: Febuxostat
Fingolimod 08.02.04 Restricted Use NICE TA 254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
Fluocinolone acetonide intravitreal implant 11.04.01 Restricted Use NICE TA 301: Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy
Glucosamine 10.01.05 Non Formulary NICE CG 177: Osteoarthritis: care and management
Golimumab 10.01.03 Restricted Use NICE TA 220: Psoriatic Arthritis - Golimumab
Golimumab 10.01.03 Restricted Use NICE TA 383:TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (Replaced TA 233 Feb 2016)
Golimumab 10.01.03 Restricted Use NICE TA 225: Rheumatoid Arthritis - Golimumab
Golimumab 01.05 Restricted Use NICE TA 329: Golimumab for moderate to severe active ulcerative colitis
Ibandronic Acid - Oral 06.06.02 Restricted Use NICE CG 80: Early and locally advanced breast cancer: diagnosis and treatment
Infliximab (Inflectra®) 01.05 Restricted Use NICE TA 187: Crohns disease- Infliximab and Adalimumab
Infliximab (Inflectra®) 01.05 Restricted Use NICE TA 163 Ulcerative colitis (acute manifestations) Infliximab
Infliximab (Inflectra®) 01.05 Restricted Use NICE TA 329: Infliximab for moderate to severe active ulcerative colitis
Infliximab (Inflectra®) 13.05.03 Restricted Use NICE TA 134: Psoriasis - Infliximab
Interferon alfa 08.02.04 Restricted Use NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ivabradine 02.06.03 Restricted Use NICE TA 267: Ivabradine in chronic heart failure
Ixekizumab 13.05.03 Restricted Use NICE TA 442: Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine 05.03.01 Restricted Use NICE CG165: Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults
Ledipasvir and sofosbuvir 05.03.03 Restricted Use NICE TA 363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lubiprostone 01.06.07 Restricted Use NICE TA 318: Lubiprostone Chronic Idiopathic Guidance
Lumacaftor - Ivacaftor 03.07 Non Formulary NICE TA 398: Lumacaftor–ivacaftor: Cystic Fibrosis
Mepolizumab 03.04.02 Restricted Use NICE TA 431: Mepolizumab for treating severe refractory eosinophilic asthma
Mianserin 04.03 Restricted Use NICE CG 91: Depression in patients with a chronic physical health problem
Mirabegron 07.04.02 Restricted Use NICE TA 290: Mirabegron in overactive bladder
Nalmefene 04.10.01 Restricted Use NICE TA 325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA 345: Naloxegol for treating opioid‑induced constipation.
Natalizumab 08.02.04 Restricted Use NICE TA 127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
Nifedipine capsule 07.01.03 Restricted Use NICE CG 25: Preterm labour and birth
Nintedanib 03.11 Restricted Use NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis
Obeticholic acid 01.09.01 Restricted Use NICE TA 443: Obeticholic acid for treating primary biliary cholangitis
Ocriplasmin 11.08.02 Restricted Use NICE TA 297: Vitreomacular traction
Omalizumab 03.04.02 Restricted Use NICE TA 278: Omalizumab in asthma
Omalizumab 03.04.02 Restricted Use NICE TA 339: Omalizumab in chronic spontaneous urticaria
Omalizumab 24.03 Restricted Use NICE TA 278: Omalizumab for treating severe persistent allergic asthma
Ombitasvir, paritaprevir, and ritonavir 05.03.03 Restricted Use NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Peginterferon alfa 08.02.04 Restricted Use NICE TA 106: Peginterferon alfa and ribavirin: mild chronic hepatitis C
Peginterferon alfa 08.02.04 Restricted Use NICE TA 200: Peginterferon alfa and ribavirin:chronic hepatitis C
Peginterferon alfa 08.02.04 Restricted Use NICE CG 165: Hepatitis B (chronic): Chronic hepatitis B in children, young people and adults
Peginterferon alfa 08.02.04 Restricted Use NICE TA 300: Peginterferon alfa and ribavirin:chronic hepatitis C in children and young people
Peginterferon alfa 08.02.04 Restricted Use NICE TA 75 Interferon alfa (pegylated and non-pegylated) and ribavirin: chronic hepatitis C
Pegloticase 10.01.04 Non Formulary NICE TA 291
Pimecrolimus 13.05.03 Restricted Use NICE TA 82: Pimecrolimus and tacrolimus for atopic dermatitis
Pirfenidone 03.11 Restricted Use NICE TA 282: Pirfenidone for treating Idiopathic Pulmonary Fibrosis
Prasugrel 02.09 Restricted Use NICE TA 317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prucalopride 01.06.07 Restricted Use NICE TA 211: Prucalopride
Quetiapine 04.02 Restricted Use NICE CG 185: Bipolar Disorder
Ranibizumab 11.08.02 Restricted Use NICE TA 155: Ranibizumab and pegaptanib for ARMD
Ranibizumab 11.08.02 Restricted Use NICE TA 274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Restricted Use NICE TA 298: Ranibizumab in pathological myopia
Ranibizumab 11.08.02 Restricted Use NICE TA 283: Ranibizumab for macular oedema secondary to retinal vein occlusion
Ribavirin 05.03.05 Restricted Use NICE TA 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribavirin 05.03.05 Restricted Use NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Ribavirin 05.03.05 Restricted Use TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Rifaximin 05.01 Restricted Use NICE TA 337: Rifaximin in hepatic encephalopathy
Rituximab 08.02.03 Restricted Use NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Roflumilast 03.01 Restricted Use NICE TA 461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Restricted Use NICE TA 221: Romiplostim
Sacubitril Valsartan 02.05.05.02 Restricted Use NICE TA 388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Secukinumab 10.01.03 Restricted Use NICE TA 407: Secukinumab in ankylosing spondylitis
Secukinumab 10.01.03 Restricted Use NICE TA 445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Restricted Use NICE TA350: Secukinumab for psoriasis
Simeprevir 05.03.03 Restricted Use NICE TA 331: Simeprevir for chronic Hepatitis C
Sofosbuvir 05.03.03 Restricted Use NICE TA 330: Sofosbuvir for chronic Hepatitis C
Sofosbuvir/valpatasvir 05.03.03 Restricted Use NICE TA 430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA 188: Somatropin (Children)
Somatropin 06.05.01 Restricted Use NICE TA 64: Somatropin (Adults)
Tacrolimus 13.05.03 Restricted Use NICE TA 82: Pimecrolimus and tacrolimus for atopic dermatitis
Tadalafil 07.04.05 Non Formulary NICE TA 273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)
Telaprevir 05.03.03 Restricted Use NICE TA 252:Telaprevir for the treatment of genotype 1 chronic hepatitis C
Teriflunomide 08.02.04 Restricted Use NICE TA 303:Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide 06.06.02 Restricted Use NICE TA 161: Osteoporosis
Ticagrelor 02.09 Restricted Use NICE TA 236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Restricted Use NICE TA 420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tobramycin 05.01 Restricted Use NICE TA 276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tocilizumab 10.01.03 Restricted Use NICE TA 247: Tocilizumab
Tocilizumab 10.01.03 Restricted Use NICE TA 373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tolvaptan 06.05.02 Restricted Use NICE TA 358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Tranexamic Acid 02.11 Formulary NICE CG 44: Heavy Menstrual Bleeding
Ustekinumab 13.05.03 Restricted Use NICE TA 180: Psoriasis-Ustekinumab
Ustekinumab (Rheumatology) 10.01.03 Restricted Use NICE TA 340: Ustekinumab in psoriatic arthritis
Vedolizumab 01.05 Restricted Use NICE TA 342: Vedolizumab – Ulcerative Colitis
Vedolizumab 01.05 Restricted Use NICE TA 352: Vedolizumab - Crohn’s disease
Leicestershire Health Community